Q-omics provides the consensus-scored MAGEB18 profile across patient tissues and cancer cell-line models. MAGEB18 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, MAGEB18 is differentially expressed in 3, with the highest sampling consensus in BRCA. Additionally, MAGEB18 RNA expression shows 8,217 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, BRCA, and TGCT as cancer lineages where MAGEB18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEB18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEB18 survival associations across molecular data types. MAGEB18 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEB18 RNA expression–survival associations across cancer types. High MAGEB18 expression shows unfavorable associations in SCLC, CESC, ACC, LIHC, DLBC and KICH. The SCLC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for MAGEB18 RNA expression.
This table summarizes MAGEB18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MAGEB18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEB18 shows higher tumor expression in BRCA, HNSC and LUSC. The BRCA box plot shows higher MAGEB18 RNA expression in tumor versus normal tissue (log2 FC = +0.019, t-test p = .030).
This table shows molecular features associated with MAGEB18 in patient tissues and cancer cell lines. In patient samples, MAGEB18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEB18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
